• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > News > Message on the passing of Dr Yves Champey from DNDi Executive Director Dr Luis Pizarro > Page 13

Message on the passing of Dr Yves Champey from DNDi Executive Director Dr Luis Pizarro

Home > News > Message on the passing of Dr Yves Champey from DNDi Executive Director Dr Luis Pizarro > Page 13

Message on the passing of Dr Yves Champey from DNDi Executive Director Dr Luis Pizarro

Yves Champey in 2013 at DNDi's 10 Year Anniversary event in Paris
19 Dec 2024

A message from DNDi Executive Director Dr Luis Pizarro: 

We are deeply saddened by news of the passing of Dr Yves Champey.  

Yves played an essential role in the creation and development of DNDi. He was a member of the “DND-working group” from 1999 to 2003 which led to the creation of DNDi, and then became our first Board Chair, until 2007.  

Dr Yves Champey

Yves designed our innovative R&D model, serving to benefit the most vulnerable affected by neglected diseases. With his expertise in pharmaceutical development, he was the first to be convinced that the best science could also benefit the most neglected. He wrote the first business plan, organised the first DNDi hires, and created the legal entity in Geneva. With an unparalleled power of conviction, he engaged the founding institutions of DNDi as well as our first major institutional donors.

His 40 years’ experience in the pharmaceutical industry, at Pfizer and Rhone Poulenc Rorer (which became Sanofi), allowed DNDi to lay the foundations of a solid R&D organisation and to very quickly gain respectability among pharmaceutical companies. Yves was a true precursor of public/private models to meet the needs of forgotten populations, convinced that everyone had to contribute. Yves continued his commitments to biotechnology companies and became the president of Genethon.

His enthusiasm, unfailing optimism, passion for Africa (his continent of birth), and his thirst to seek innovative solutions through science, allowed DNDi not only to overcome the difficulties inherent in new organisations but also to remain unique in the world of public health.

Yves remained a faithful friend of DNDi, continuing to keep himself informed of our journey. On behalf of the whole DNDi team, I express my deepest condolences to his family, colleagues, and friends.

Watch Dr Champey tell the story of DNDi’s creation at DNDi’s 10 Year Anniversary event [in French]:

Read, watch, share

Loading...
Two people working in a lab
Press releases
24 Jun 2024

Paediatric malaria treatment developed in Brazil by not-for-profit organizations distributed to Indigenous children in the Amazon region

Two healthcare workers
Press releases
12 Jun 2024

New framework for visceral leishmaniasis elimination launched for Eastern Africa

LEAP Platform video thumbnail
Videos
30 May 2024

Celebrating 20 Years of LEAP: Innovation and Impact

Statements
28 May 2024

DNDi interventions at the 77th World Health Assembly

Dr Loyce Faith Nangiro visting a patient on the ward
Stories
23 May 2024

Defying the odds: One doctor’s remarkable journey to helping patients with kala-azar

Statements
21 May 2024

DNDi’s briefing note for 77th World Health Assembly

Lab equipment
Press releases
9 May 2024

DNDi welcomes GHIT Fund’s renewed support to optimize novel compounds to treat Chagas disease

Researcher in a lab
Press releases
23 Apr 2024

Promising patient-friendly oral drug against visceral leishmaniasis enters Phase II clinical trial in Ethiopia

VIEW ALL

Help neglected patients

To date, we have delivered thirteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films, and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license